Abstract
It is unclear what the risk of allergic reactions is with appropriately given dilute i.v. redback spider antivenom (RBSAV). Ninety‐five i.v. administrations of RBSAV referred from January 2001 to November 2006 were reviewed. All patients had local pain, 72% radiating pain, 57% diaphoresis and 39% systemic effects. Four patients (4%) had immediate systemic hypersensitivity reactions: none were severe, one was moderate and three mild. In 32 patients followed up for 2 weeks, three (10%) developed serum sickness. RBSAV given i.v. had a low reaction rate.

This publication has 13 references indexed in Scilit: